达帕格利弗洛辛在患有膜性腎病症的患者中的作用
Glenn M Chertow1, Hiddo Lambers Heerspink2,3, Patrick B Mark4,5
1Departments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, CA, USA.
Glomerular diseases
|August 15, 2024
概括
达帕格利弗洛辛在患有膜性脏病的患者中对脏疾病进展和白蛋白尿产生了有利影响. 虽然由于样本规模较小,该药物在统计学上并不显著,但在这个DAPA-CKD分析中显示了改善结果的趋势.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 临床药理学 临床药理学
背景情况:
- 膜性病 (MN) 经常进展到末期病 (ESKD),尽管目前的治疗方法.
- 需要有效的疗法来减缓MN的病进展.
研究的目的:
- 评估大帕格利弗洛辛在患有膜性病的患者中的安全性和有效性.
- 在DAPA-CKD试验中评估达帕格利弗洛辛对病进展和白蛋白尿的影响.
主要方法:
- 对DAPA-CKD试验的预规定的分析包括患有MN的患者,随机分配给达帕格利弗洛辛 (每天10毫克) 或安慰剂.
- 患者的eGFR为25-75mL/min/1.73m2和UACR为200-5,000mg/g,平均被跟踪时间为2.4年.
- 主要终点是持续的eGFR下降,ESKD或死亡的复合;探索性终点包括eGFR斜率和UACR.
主要成果:
- 19名患者接受了达帕格利弗洛辛,24名患者接受了安慰剂.
- 与安慰剂 (21%) 相比,接受达帕格利弗洛辛的患者较少 (11%) 经历了初级复合终点.
- 与安慰剂相比,达帕格利弗洛辛显示出较慢的eGFR下降趋势和显着减少白尿 (UACR).
结论:
- 达帕格利弗洛辛在患有MN的患者中对脏疾病进展和白蛋白尿产生了普遍有利的影响.
- 这项研究在正式的统计推断方面缺乏实力,但结果表明潜在的好处.
- 需要进一步的研究来证实达帕格利弗洛辛在MN的疗效.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
526
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
8.4K
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:11Renal Failure: Dose Adjustments
71
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
71
01:16Antihypertensive Drugs: Action of Diuretics
636
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
636
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
569
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
569